The FDA has granted fast track designation to OPN-6602, an investigational oral dual inhibitor of EP300 and CREB-binding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results